Nuvation Bio (NUVB)
(Delayed Data from NYSE)
$3.71 USD
+0.01 (0.27%)
Updated Oct 2, 2025 04:00 PM ET
After-Market: $3.70 -0.01 (-0.27%) 6:38 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
NUVB 3.71 +0.01(0.27%)
Will NUVB be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for NUVB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NUVB
Nuvation Bio Inc. (NUVB) Just Flashed Golden Cross Signal: Do You Buy?
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates
NUVB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia Pharmaceuticals (ACAD) Tops Q2 Earnings and Revenue Estimates
All You Need to Know About Nuvation Bio (NUVB) Rating Upgrade to Buy
Nuvation Bio Inc. (NUVB) Reports Q1 Loss, Tops Revenue Estimates
Other News for NUVB
MACD Bullish Signal Line Cross appears for NUVB after 0.54% move
Is NUVB gaining bullish strength? Crossed Above 20 Day Moving Average shows up after soaring 14.91%
Nuvation Bio (NUVB) Surges 13% Following Phase 3 Enrollment and Buy Rating
NUVB Stock Surges: Key Developments Driving Growth
Nuvation Bio up after enrollment update, Jefferies’ bullish view